Ifosfamide

• 

  Subject Areas on Research

  • A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma. 
  • A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. 
  • A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study. 
  • A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • Active chemotherapy for metastatic stromal cell tumor of the testis. 
  • Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma. 
  • Adjuvant chemotherapy for osteosarcoma may not increase survival after neoadjuvant chemotherapy and surgical resection. 
  • Adult testicular sarcoma: presentation, evaluation, and treatment. 
  • Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. 
  • Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck cancers: a phase I Brown University Oncology Group dose escalation study (HN-93). 
  • Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. 
  • Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. 
  • Cerebral atrophy in an infant following treatment with ifosfamide. 
  • Epirubicin and ifosfamide in metastatic breast cancer. 
  • Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study. 
  • Evaluating a critically ill patient with metabolic acidosis: the ifosfamide paradigm. 
  • Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. 
  • Giant thoracic liposarcoma treated with induction chemotherapy followed by surgical resection. 
  • High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. 
  • High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. 
  • Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. 
  • Ifosfamide enantiomers: pharmacokinetics in children. 
  • Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. 
  • Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. 
  • Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas. 
  • Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. 
  • Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. 
  • Pancreatoblastoma in a teenage patient. 
  • Pathologic complete response of a malignant peripheral nerve sheath tumor in the lung treated with neoadjuvant Ifosfamide and radiation therapy. 
  • Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. 
  • Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. 
  • Plasma glutathione peroxidase and its relationship to renal proximal tubule function. 
  • Primary extracranial rhabdoid tumors. Clinicopathologic features and response to ifosfamide. 
  • Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. 
  • Progressive glomerular toxicity of ifosfamide in children. 
  • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. 
  • Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. 
  • Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. 
  • Sickness behavior clustering in children with cancer. 
  • Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer. 
  • Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. 
  • The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.